Nebulised antibiotics for adults with cystic fibrosis

A K Webb, M E Dodd

During adolescence most patients with cystic fibrosis become chronically colonised with *Pseudomonas aeruginosa*. Acquisition of this organism is associated with a worse prognosis.¹

The emphasis of care is to delay the progression of pulmonary sepsis which is responsible for almost the total mortality of patients with cystic fibrosis. Repeated sputum culture of *P aeruginosa* confirms chronic infection and it is then impossible to eradicate. Regular courses of intravenous antibiotics have improved survival by reducing sputum load and maintaining pulmonary function, but they interfere with the activities of daily living. The prescription of nebulised antibiotics for domiciliary use by patients with cystic fibrosis is increasing. However, experienced physicians working in cystic fibrosis centres have shown considerable variability in their prescribing practices.²

Clinical indications

DELAY OR PREVENTION OF CHRONIC COLONISATION WITH *P AERUGINOSA*

The introduction of nebulised colistin at the time of initial colonisation with *P aeruginosa* may reduce and delay chronic colonisation,^{3,4} defined as three consecutive positive sputum cultures within six months. In an uncontrolled trial nebulised colistin given to seven children with cystic fibrosis reduced the frequency of positive cultures from 46% to 6%.³ In a controlled prospective study a combination of nebulised colistin and oral ciprofloxacin significantly prevented or delayed chronic infection with *P aeruginosa* for 18 months.⁴ These results suggest a role for nebulised antibiotics when the organism is first isolated from sputum. No trials have been published on the use of nebulised antibiotics at the time of diagnosis of cystic fibrosis before *P aeruginosa* has been cultured from the sputum.

PREVENTION OF CLINICAL DETERIORATION IN PATIENTS CHRONICALLY INFECTED WITH *P AERUGINOSA*

Regular aerosolised antibiotics have been used for patients chronically infected with *P aeruginosa* to reduce the rate of deterioration. An early controlled trial compared twice daily administration of 80 mg nebulised gentamicin combined with 1 g carbenicillin against placebo.⁵ In the group that received the active drugs for six months there was a reduction in hospital admissions for infective exacerbations

and pulmonary function was maintained. Aerosolised therapy was cost effective because of the reduced hospital costs.

Ceftazidime was compared with a combination of gentamicin with carbenicillin in a crossover study in which saline was used as the placebo.⁶ Each arm of the crossover period lasted for four months. Both active drug regimens were equally effective in increasing body weight and improving lung function compared with placebo. These results suggest that only one nebulised antibiotic is required for efficacy.

A recent short term study recruited 71 patients into a controlled trial of placebo versus high dose nebulised tobramycin, 600 mg/day.⁷ The high dose of tobramycin was used to increase the bactericidal dose of antibiotic in the sputum against tobramycin sensitive *P aeruginosa*. There was a significant improvement in pulmonary function and a reduction of *P aeruginosa* in the sputum. Bacterial resistance patterns were similar during the active and placebo part of the study. No ototoxicity or nephrotoxicity was observed. These results suggest that high dose nebulised tobramycin is clinically effective, safe, and does not promote bacterial resistance.

Nebulised tobramycin, 80 mg twice daily, was evaluated in a long term open study (mean duration 20 months) in 14 patients with a mean age of 13.3 years.⁸ Clinical parameters improved and hospital admissions decreased. There was a reduction in one or more inflammatory markers (antibody serum titres to *P aeruginosa*, elastase, exotoxin A, alkaline phosphatase) in eight patients. No tobramycin was detected in 50 of 70 blood samples. Intermittent tobramycin resistance developed in five patients (but only in 6.2% of strains) and persisted in only one patient at the end of the study. These results suggest that long term nebulised aminoglycosides are safe, clinically effective and, by reducing the bacterial antigen load, may diminish the systemic host immune response.

A review of five randomised controlled trials showed benefit for nebulised antipseudomonal antibiotic therapy with no demonstrable adverse effects.⁹ There is no evidence to suggest that nebulised antibiotics used as an adjunct to a course of intravenous antibiotics augment clinical improvement.¹⁰ Nebulised antibiotics should not be used as an alternative to intravenous antibiotics for an infective exacerbation.

Assessment and administration

PATIENT ASSESSMENT

Patients should be carefully assessed before treatment with nebulised antibiotics is started.

Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester M23 9LT, UK
A K Webb
M E Dodd

Correspondence to:
Dr A K Webb.

A recent sputum culture should be used to determine which antibiotic to prescribe according to resistance patterns. Colistin is infrequently used intravenously and resistance to *P aeruginosa* is uncommon. Each patient should be given a hospital supervised dose after chest physiotherapy and spirometric tests should be performed before and immediately after challenge. Maximal bronchoconstriction to nebulised antibiotics usually occurs immediately after administration.¹¹ Bronchoconstriction is usually related to hypertonicity of the antibiotic solution.^{12 13} Prevention of bronchoconstriction may be achieved by altering the tonicity by dilution with water or half normal saline.¹⁴

It is recommended that patients use nebulised antibiotics after physiotherapy and bronchodilators to ensure maximum deposition and protection from bronchoconstriction.¹¹ Patients should be provided with a mouthpiece rather than a face mask to maximise pulmonary deposition.¹⁵ Relaxed tidal volume breathing through the mouth and not the nose¹⁶ is recommended for patients using nebulised antibiotics. Finally, patient compliance levels should be checked after a period of domiciliary use. Irregular usage is not recommended and is a reason for cessation.

DISTRIBUTION OF NEBULISED ANTIBIOTIC IN THE LUNG

Overall, about 10% of a nebulised drug is delivered to the lungs. A study in volunteers and five mechanically ventilated patients given 300 mg nebulised tobramycin found that 5.5% of the initial dose was excreted in the urine of both groups. A piece of normal lung tissue was removed from the ventilated patients who were undergoing thoracotomy and mean concentrations of 5.5 µg/g and 3.6 µg/g were found at four and 12 hours.¹⁷

Systemic absorption of nebulised aminoglycosides does occur in patients but the amount absorbed proportional to the dose delivered as measured by urinary excretion is small (0.5%).¹⁸

Although the concentration of aerosolised antibiotic in bronchial secretions may not always achieve bactericidal levels, sublethal concentrations may diminish bacterial virulence factors.¹⁹

CHOICE OF ANTIBIOTIC AND FORMULATION

The polymyxin antibiotic colistin and the aminoglycosides tobramycin and gentamicin are the most commonly prescribed nebulised antibiotics. Colistin is currently the only antibiotic licensed in the UK for inhalation. Tobramycin probably has greater activity than gentamicin against *P aeruginosa*. Infrequently used antibiotics for nebulisation include ceftazidime, carbenicillin, and ticarcillin. Colistin has excellent antipseudomonal activity and is probably the first line choice for nebulised use. *Pseudomonas aeruginosa* resistance is rare but *Burkholderia cepacia* resistance is total.

Table 1 Commonly used nebulised antibiotics

Antibiotic	Daily dose
Colistin*	2 mega units 12 hourly
Gentamicin	80 mg 12 hourly
Tobramycin	80 mg 12 hourly

* Colistin is the only antibiotic licensed in the UK for inhalation.

Table 2 Isotonic solutions of colistin

Dose	Volume fill	Solvent
2 mega units	4 ml	2 ml water + 2 ml 0.9% NaCl
2 mega units	2.5 ml	1.5 ml water + 1 ml 0.9% NaCl
2 mega units	3 ml	2 ml water + 1 ml 0.9% NaCl

Nebulised antibiotics are prescribed twice a day for domiciliary use. Drugs and dosages are presented in tables 1 and 2.

ANTIBIOTIC SAFETY

Resistance

Concern has been expressed that bacterial resistance will develop with the administration of sublethal twice daily doses of aerosolised antibiotics. Resistance does occur but is often intermittent and not related to clinical deterioration.^{5 8} There is no confirmatory evidence that the use of aerosolised antibiotics in the presence of resistant bacteria leads to increased colonisation of the bronchial tree with these resistant organisms. *Burkholderia cepacia* is always resistant to colistin which should not be used if it is the only pathogen in the sputum. There is no published literature on the use of nebulised antibiotics for *B cepacia*.

Environmental safety

Concern has been expressed that the liberal use of nebulised antibiotics may be a health hazard to medical personnel and constitute a threat to the hospital and home environment. Staff caring for patients using nebulised antibiotics have experienced bronchoconstriction and cutaneous rashes. Although it has been suggested that polluting the hospital atmosphere may lead to the establishment of resistant organisms, particularly on intensive care units where patients may receive nebulised antibiotics following transplantation to maintain airways sterility, there is no published medical evidence to support this.

In hospital a nebuliser should be fitted with a high efficiency breathing filter on the expiratory port to prevent environmental contamination and patients with cystic fibrosis can usually stop their nebulised antibiotics when they are receiving intravenous antibiotics. It is advisable for patients to receive them in a separate area.

At home patients should nebulise their antibiotics in a separate room. They do not need to vent their exhaled antibiotics for safety reasons although they may wish to do so to eliminate the odour. If they have a sibling with cystic fibrosis they should use a filter.

Table 3 Order of preference for compressor/nebuliser systems for nebulised antibiotics

(1) Standard flow rate compressor (6 l/min) with a breath enhanced open vent nebuliser. This is suitable for children over two years and adults.
(2) High flow rate compressor (8 l/min) with a breath enhanced open vent nebuliser.
(3) High flow rate compressor (8 l/min) with a Venturi nebuliser. This is recommended if compliance is a problem as nebulisation time is reduced.
(4) Standard flow rate compressor (6 l/min) with a Venturi nebuliser.

Mouthpieces rather than face masks should be used except for infants or younger children who will not tolerate them.

Patient safety

The respiratory side effects of aerosolised antibiotics are mainly limited to bronchoconstriction at time of delivery. Cutaneous rashes are rare but may occur with nebulised drugs. A sore mouth may be due to candidiasis although the incidence is not known. If a mask is used the face should be washed after antibiotic nebulisation.

During pregnancy intravenous aminoglycosides cross the placenta. Although repeated courses of high dose intravenous aminoglycosides have been associated with deafness and renal damage,²⁰ these side effects have not been reported with nebulised therapy.⁸ Aerosolised antibiotics should be prescribed with caution during pregnancy but, on the available evidence, are not contraindicated.

Nebulisers may act as a source of bacterial contamination.^{21 22} Nosocomial acquisition of *Burkholderia cepacia* has been associated with the use of humidifiers and nebulisers²³ and respiratory equipment has been implicated as the source of spread of *B cepacia* in immune suppressed patients.²⁴ It is recommended that patients should clean their nebulisers after every use and some can be placed in a dishwasher.²² It is important that cystic fibrosis patients colonised with *B cepacia* should have their own compressors and they should not be used subsequently by patients infected with *P aeruginosa*. An electrical compressor should have an inlet filter which should be changed every three months. There should also be a bacterial filter in line to prevent the patient receiving contaminants from the compressor. These should be changed annually or between patients. Incorrect care of a nebuliser/compressor system may result in an inefficient system for drug delivery and a potential hazard to the patient and environment.

ANTIBIOTIC DELIVERY

Antibiotics are available as a solution or powder and are reconstituted as a solution using saline or water to a volume of 4 ml (2.5 ml for a low residual volume nebuliser). Nebulisation should take no longer than 10 minutes in order to ensure maximum compliance. The combination of an electrical compressor and a nebuliser must then be matched to maximise

effective delivery of the nebulised antibiotic to the patient. The requirements of a system for nebulising antibiotics may differ from other solutions. Continuous improvements are taking place to meet patient requirements. Some recommended systems are shown in table 3.

1 Wilmott RW, Tyson SL, Mathews DJ. Cystic fibrosis survival rate: the influence of allergy and *Pseudomonas aeruginosa*. *Am J Dis Child* 1985;**139**:669-71.

2 Taylor R, Hodson M. Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire. *Respir Med* 1993;**7**:535-40.

3 Littlewood J, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early colonisation in cystic fibrosis. *Lancet* 1985;**ii**:865.

4 Valerius NH, Koch C, Hoiby N. Prevention of chronic *Pseudomonas aeruginosa* colonisation in cystic fibrosis by early treatment. *Lancet* 1991;**338**:725-6.

5 Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of *Pseudomonas aeruginosa* infection in patients with cystic fibrosis. *Lancet* 1981;**iii**:1137-9.

6 Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients infected with *Pseudomonas aeruginosa*. *Br J Dis Chest* 1987;**81**:272-8.

7 Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolised tobramycin in patients with cystic fibrosis. *N Engl J Med* 1993;**328**:1740-6.

8 Steinkamp G, Tummler B, Gappa M, Albus A, Potel J, Goring G, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. *Pediatr Pulmonol* 1989;**6**:91-8.

9 Mukhopadhyay S, Singh M, Cater JJ, Ogston S, Franklin M, Olver RE. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. *Thorax* 1996;**51**:364-8.

10 Stephens D, Garey N, Isles A, Levison H, Gold R. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. *Pediatr Infect Dis* 1983;**2**:209-11.

11 Maddison J, Dodd M, Webb AK. Nebulised colistin causes chest tightness in adults with cystic fibrosis. *Respir Med* 1994;**88**:145-7.

12 Chua HL, Collis GG, Le Souef PN. Bronchial response to nebulised antibiotics in children with cystic fibrosis. *Eur Respir J* 1990;**3**:114-6.

13 Littlewood JM, Smye SW, Cunliffe H. Aerosol antibiotic treatment in cystic fibrosis. *Arch Dis Child* 1993;**68**:788-92.

14 Dodd ME, Maddison J, Abbott J, Webb AK. The effect of the tonicity of nebulised colistin on chest tightness and lung function in adults with cystic fibrosis. *Eur Respir J* 1993;**6**:515S.

15 Everard ML, Hardy JG, Milner AD. Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. *Thorax* 1993;**48**:1045-6.

16 Newman SP, Woodman G, Clarke SW. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. *Thorax* 1988;**43**:318-22.

17 Le Conte P, Potel G, Peltier P, Horeau D, Caillon J, Juvin ME, et al. Lung distribution and pharmacokinetics of aerosolised tobramycin. *Am Rev Respir Dis* 1993;**147**:1279-82.

18 Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. *Pediatr Pulmonol* 1989;**7**:265-71.

19 Geers TJ, Cooke RE. The effect of sublethal levels of antibiotics on the pathogenicity of *Pseudomonas aeruginosa* from tracheal tissue. *J Antimicrob Chem* 1987;**19**:569-78.

20 McRorie T, Bosso J, Randolph L. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high frequency audiometry. *Am J Dis Child* 1989;**143**:1328-32.

21 Barnes KL, Clifford R, Holgate ST, Murphy D, Comber P, Bell E. Bacterial contamination of home nebulisers. *BMJ* 1987;**295**:812.

22 Pitchford KC, Corey M, Highsmith AK, Periman R, Banatyne R, Gold R, et al. *Pseudomonas* species contamination of cystic fibrosis patients' home inhalation equipment. *J Pediatr* 1987;**111**:212-6.

23 Burdge DR, Nakiena EM, Noble MA. Case-control and vector studies of nosocomial acquisition of *Pseudomonas cepacia* in adult patients with cystic fibrosis. *Infect Control Hosp Epidemiol* 1993;**14**:127-30.

24 Yamagishi Y, Fujita J, Takigawa K, Negayama K, Nakazawa T, Takahara J. Clinical features of *Pseudomonas cepacia* pneumonia in an epidemic among immunocompromised patients. *Chest* 1993;**103**:1706-9.